By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: SEC Lawsuit Against FDA Chemist for Insider Trading
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > SEC Lawsuit Against FDA Chemist for Insider Trading
Business

SEC Lawsuit Against FDA Chemist for Insider Trading

BarbaraDuck
BarbaraDuck
Share
2 Min Read
SHARE

Insider trading issues seem to reach all levels of society and not just those working in the financial areas of business. I guess when you stop and think if you are working as a chemist and have this type of information ahead of time, it could be tempting. The article continues on to say that he did not use his or his wife’s account but rather seven accounts held by other individuals but eventually the money made it back to the chemist’s account. He profited from investing ahead on 19 investments and sold other short before the negatives reached the general news. No kickback mentioned, he just seemed to be on his own investment path here. Darn it’s getting harder for the FDA to keep folks these days. BD

The Securities and Exchange Commission sued a U.S. Food and Drug Administration chemist, claiming he reaped $3.6 million from trading on confidential information related to drug-approval applications. Cheng Yi Liang, 57, made trades involving 19 companies from as early as July 2006 in advance of at least 27 announcements of FDA decisions on drug applications, the SEC said in a lawsuit filed today at U.S. District Court in Greenbelt, Maryland. The chemist, who worked for the FDA’s Center for Drug Evaluation and Research, violated his duty as a federal employee not to engage in financial transactions using nonpublic government information and not to use such information for his personal benefit, according to the SEC, which is seeking disgorgement of illegal profits and unspecified fines.

TAGGED:FDAhealth care law
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Nursing Trends That Are Quietly Solving the Rural Healthcare Crisis
Nursing Trends That Are Quietly Solving the Rural Healthcare Crisis
Career Nursing
April 13, 2026
pharma response to chronic illness
Inside a Marco Pharma Practitioner’s Approach to Chronic Illness
Global Healthcare
April 12, 2026
doctor talking on the phone
How Home System Conditions Shape Daily Health and Long Term Comfort
Health
April 9, 2026
healthcare communication
Independent Practices Should Keep Real People at the Heart of Patient Communication
Global Healthcare
April 8, 2026

You Might also Like

Image
BusinesseHealthSocial Media

Beyond the Buzz: 7 Reasons Healthcare Professionals Should Blog

August 29, 2014
patient-centered healthcare
Business

Person-Centered HealthCare: How to Deliver Patient-Centered Care

April 26, 2013

How to Improve Patient Relationship this Holiday Season

November 20, 2015

Veterans and mHealth: A Sensible Patient Engagement Strategy

September 17, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?